IRIS
CARACCIOLO, DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 926
EU - Europa 647
AS - Asia 431
SA - Sud America 54
AF - Africa 7
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 3
Totale 2.075
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 899
IT - Italia 385
SG - Singapore 305
DE - Germania 97
CN - Cina 61
GB - Regno Unito 57
BR - Brasile 47
FI - Finlandia 30
SE - Svezia 30
IN - India 21
CA - Canada 20
HK - Hong Kong 19
NL - Olanda 12
FR - Francia 9
EU - Europa 7
AT - Austria 6
BD - Bangladesh 5
JP - Giappone 5
RU - Federazione Russa 5
ZA - Sudafrica 5
ES - Italia 4
MX - Messico 4
AU - Australia 3
CZ - Repubblica Ceca 3
EC - Ecuador 3
UA - Ucraina 3
CH - Svizzera 2
EG - Egitto 2
IQ - Iraq 2
IR - Iran 2
LB - Libano 2
TR - Turchia 2
VN - Vietnam 2
CL - Cile 1
CO - Colombia 1
EE - Estonia 1
GE - Georgia 1
GR - Grecia 1
JM - Giamaica 1
MY - Malesia 1
OM - Oman 1
PA - Panama 1
PK - Pakistan 1
PL - Polonia 1
PY - Paraguay 1
RO - Romania 1
SA - Arabia Saudita 1
TT - Trinidad e Tobago 1
VE - Venezuela 1
Totale 2.075
Salva come PNG Salva come JPEG
Città #
Singapore 186
Chandler 152
Munich 71
Santa Clara 64
Chicago 50
Ashburn 45
London 45
Catanzaro 44
Lawrence 44
Princeton 44
Milan 43
Turku 22
Naples 19
Wilmington 18
Hong Kong 16
Beijing 15
Rome 15
Des Moines 13
Ottawa 13
Carbonia 12
Parma 12
Los Angeles 11
Boardman 9
Brooklyn 8
Cosenza 8
Ercolano 8
Helsinki 8
Redwood City 8
San Nicola Manfredi 8
Santo Stefano di Rogliano 8
Afragola 7
Melito di Porto Salvo 6
New York 6
São Paulo 6
Catania 5
Columbus 5
Guangzhou 5
Reggio Calabria 5
Settingiano 5
Shanghai 5
The Dalles 5
Brescia 4
Dallas 4
Decollatura 4
Hanover 4
Jiaxing 4
Mountain View 4
New Delhi 4
Pune 4
Redmond 4
Seattle 4
Acquaviva delle Fonti 3
Ahmedabad 3
Berlin 3
Boston 3
Cape Town 3
Castrovillari 3
Charlotte 3
Chennai 3
Dhaka 3
Frankfurt am Main 3
Mileto 3
Nuremberg 3
Olomouc 3
Palermo 3
Paola 3
Phoenix 3
San Antonio 3
San Francisco 3
Stockholm 3
Treviso 3
Washington 3
6th of October City 2
Agrigento 2
Andover 2
Assago 2
Atlanta 2
Beirut 2
Bologna 2
Brighton 2
Buffalo 2
Campobello di Licata 2
Ceglie Del Campo 2
Council Bluffs 2
Delhi 2
Esslingen am Neckar 2
Gesuiti 2
Grottaglie 2
Hefei 2
Jackson 2
Johannesburg 2
Juiz de Fora 2
Leawood 2
Madrid 2
Mexico City 2
Montreal 2
Paris 2
Richmond 2
Rio de Janeiro 2
Romainville 2
Totale 1.238
Salva come PNG Salva come JPEG
Nome #
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 85
miR-22 suppresses DNA ligase III addiction in multiple myeloma 84
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 81
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 69
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 65
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 62
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 55
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 52
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 49
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 49
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 46
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 46
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 44
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 44
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. 44
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 42
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 41
Mir-221/222 are promising targets for innovative anticancer therapy 39
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 39
From single level analysis to multi-omics integrative approaches: A powerful strategy towards the precision oncology 39
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 39
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 37
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 37
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 37
Mmrf-commpass data integration and analysis for identifying prognostic markers 37
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 36
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 36
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 35
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 35
Distinctive role of the systemic inflammatory profile in non-small-cell lung cancer younger and elderly patients treated with a pd-1 immune checkpoint blockade: A real-world retrospective multi-institutional analysis 35
Integration of DNA Microarray with Clinical and Genomic Data 34
Pharmacogenomics biomarker discovery and validation for translation in clinical practice. 33
From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario 32
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives 31
The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma 31
Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats 31
null 31
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis 29
Mirnas and lncrnas as novel therapeutic targets to improve cancer immunotherapy 29
Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes 28
Alternative non-homologous end-joining: Error-prone dna repair as cancer’s achilles’ heel 28
An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma 27
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity 26
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 25
From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology 25
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 23
Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma 22
MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches 22
Tools in Pharmacogenomics Biomarker Identification for Cancer Patients 20
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma 20
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells 19
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells 19
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts 18
The potential role of miRNAs in multiple myeloma therapy 17
Frontline therapy CLL without 17p del/p53 aberrations: systematic review and Bayesian network meta-analysis 15
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma. 15
Synthetic miR-22 impairs NHEJ repair sensistizing multiple myeloma cells to bortezomib-induced BRCAness 15
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: In vitro and in vivo anti-tumor activity 14
The potential role of miRNAs in multiple myeloma therapy 14
UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma 13
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity 13
Targeting oncogenic pri-miR-17-92 in multiple myeloma: molecular findings and therapeutic potential 13
Immunomodulatory activity of microRNAs: potential implications for multiple myeloma treatment. 12
Severe Hemodynamic Instability in a Young Pregnant Woman with Massive Pericardial Effusion and Pulmonary Embolism Secondary to Primary Mediastinal Non-Hodgkin's Lymphoma 11
TERRA G-quadruplex stabilization behind the anti-multiple myeloma activity: Novel insights about resveratrol pleiotropic effects 11
Totale 2.205
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.837
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.837
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021132 4 2 9 10 12 9 11 10 25 20 15 5
2021/2022179 4 0 0 27 7 5 11 30 37 31 24 3
2022/2023541 95 29 32 21 64 38 6 39 76 54 68 19
2023/2024320 86 32 36 22 16 83 7 6 1 5 10 16
2024/2025886 88 26 29 37 59 132 39 45 70 10 130 221
2025/202698 98 0 0 0 0 0 0 0 0 0 0 0
Totale 2.205